testosterone

FDA Drug Profile — Testosterone, TESTOSTERONE, testosterone, Natesto nasal gel, Testopel

testosterone is listed in the FDA National Drug Code directory with 24 NDC codes, marketed under brand names including Testosterone, TESTOSTERONE, testosterone. Available dosage forms: gel, solution, gel, metered, pellet, powder.

Drug details

Generic Name
testosterone
Brand Names
Testosterone, TESTOSTERONE, testosterone, Natesto nasal gel, Testopel, Testim
Application Number
NDA022309
Sponsor
Prasco Laboratories
NDC Codes
24
Dosage Forms
GEL, SOLUTION, GEL, METERED, PELLET, POWDER
Routes
TRANSDERMAL, TOPICAL, NASAL, SUBCUTANEOUS
Active Ingredients
TESTOSTERONE

Indications and Usage

1 INDICATIONS AND USAGE Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired); testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum concentrations and gonadotropins (FSH, LH) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropic or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma or radiation. These men have low testosterone serum-concentrations but have gonadotropins in the normal or low range. Limitations of use: Safety and efficacy of Testosterone Topical Solution in men with “age-related hypogonadism' (also referred to as “late-onset hypogonadism”) have not been established. Safety and efficacy of Testosterone Topical Solution in males < 18 years old have not been established [see Use in Specific Populations ( 8.4 )]. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) ( 1 ) Hypogonadotropic hypogonadism (congenital or acquired) ( 1 ) Limitations of use: Safety and efficacy of Testosterone Topical Solution in men with “age-related hypogonadism” have not been established. ( 1 ) Safety and efficacy of Testosterone Topical Solution in males < 18 years old have not been established. ( 8.4 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.